What is the absolute risk reduction for the primary composite end point when com

Do you need this or any other assignment done for you from scratch?

We have qualified writers to help you.

We assure you a quality paper that is 100% free from plagiarism and AI.

You can choose either format of your choice ( Apa, Mla, Havard, Chicago, or any other)

NB: We do not resell your papers. Upon ordering, we do an original paper exclusively for you.

NB: All your data is kept safe from the public.

Click Here To Order Now!

What is the absolute risk reduction for the primary composite end point when com

What is the absolute risk reduction for the primary composite end point when comparing alirocumatb to placebo? Provide your answer in decimal format with three decimal places (eg 0.007, 0.070, 0.700)
We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patiernts who had an
acute coronary syndrome 1 to 12 months earier. Patients were randomly assigned to receive alirocumab subcutaneously
ta dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks.
RESULTS:
A composite primary end-point event occurred in 1207 patients in the alirocumab group and in 1,858 patients in the
placebo group. A total of 334 patients (3,5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died
(hazard ratio, 0.85; 95% C1, 0.73 to 098) The incidence of adverse events was similar in the two groups, with the
exception of local injection-site reactions (3.8% in the alirocumab group vs, 2.1% in the placebo group).

Do you need this or any other assignment done for you from scratch?

We have qualified writers to help you.

We assure you a quality paper that is 100% free from plagiarism and AI.

You can choose either format of your choice ( Apa, Mla, Havard, Chicago, or any other)

NB: We do not resell your papers. Upon ordering, we do an original paper exclusively for you.

NB: All your data is kept safe from the public.

Click Here To Order Now!